Cardiology Online - International Academy of Cardiology
 
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Congresses
   Journals
   Organizations
   Institutions
   Books
   Research
   Guidelines
   Discussion Groups
   Webcourses
   Websites
   Job Opportunities
   Contact Us




 

 

 

 


IAC 2018

 

RAPAMYCIN PROTECTS DIABETIC RABBIT HEARTS AGAINST ISCHEMIA/REPERFUSION INJURY BY REGULATING PTEN-AKT SIGNALING (Invited Lecture)



Anindita Das, Ph.D., Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA

 

Background: Diabetes is a major risk factor for myocardial infarction (MI). Persistent activation of the mammalian target of rapamycin (mTOR) leads to diabetic complications and plays a critical role in myocardial reperfusion injury following MI. mTOR inhibition with rapamycin (RAPA) at reperfusion preserves cardiac function with reduction of myocardial infarction in type 2 diabetic mice. To demonstrate the clinical potential of these novel observations, we examined the effect of RAPA in a conscious diabetic rabbit model of MI and its associated molecular mechanism.
Methods and Results: Control (n=12) and diabetic (DM, n=34; induced by alloxan monohydrate treatment) male New Zealand rabbits were subjected to conscious 45 min ischemia and 3 days of reperfusion by inflating/deflating the hydraulic balloon occluder implanted on the top of the coronary artery. RAPA (0.25 mg/kg, i.v.) or DMSO (vehicle) was infused 5 min before reperfusion. RAPA treatment at the onset of reperfusion significantly reduced infarct size and apoptosis as compared to control and DM. Plasma troponin I was also reduced in RAPA-treated diabetic rabbits following I/R injury. Phosphorylation of S6 (marker of mTORC1) was increased, while the phosphorylation of AKT (marker of mTORC2) was reduced following I/R injury in diabetic rabbit heart. Interestingly, RAPA treatment inhibited diabetes-induced phosphorylation of S6, but restored phosphorylation of AKT. Moreover, the cardiac microRNA-302a, a regulator of anti-oxidative and anti-apoptosis through activating AKT signaling, was reduced with a concomitant elevation of its target PTEN following I/R in diabetic rabbit heart. RAPA treatment restored the level of miR-302a and blunted the induction of PTEN.
Conclusion: Rapamycin could be a promising drug in attenuation of reperfusion injury in diabetic subjects following acute MI by regulating of microRNA-302a-PTEN-AKT signaling.

 

 

©1998-2020 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.
CardiologyOnline.com